Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific’s Vercise Gevia DBS system receives CE Mark approval

Boston Scientific’s Vercise Gevia DBS system receives CE Mark approval

7th June 2017

Boston Scientific has announced that its Vercise Gevia deep brain stimulation (DBS) system has received European CE Mark approval.

The rechargeable magnetic resonance conditional device is indicated for the treatment of movement disorder symptoms in patients with a variety of conditions, including Parkinson's disease, dystonia and essential tremor.

It incorporates Vercise Neural Navigator 2 software with STIMVIEW Technology, which allows clinicians to visualise the stimulation field while configuring DBS stimulation programmes for patients, as well as offering a 25-year battery life.

The products in the Vercise Directional range are the only DBS solutions that offer fine control over the size, shape and direction of stimulation, allowing neural targets to be selected and isolated precisely.

Maulik Nanavaty, senior vice-president and president of neuromodulation at Boston Scientific, said: "Boston Scientific is dedicated to providing transformative technology to equip clinicians and improve the lives of patients."

Other products in the range include the Vercise Primary Cell and Vercise Gevia platforms, with Vercise Cartesia Directional Leads.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836635-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.